Calcitriol treatment increases serum levels of the soluble receptor of advanced glycation end products in hemodialysis patients with secondary hyperparathyroidism

Tohoku Journal of Experimental Medicine

Volumn 230, Issue 1, 2013, Pages 59-66

  Sung, Ji Yoon ^a   Chung, Wookyung ^a   Kim, Ae Jin ^a   Kim, Hyung Soo ^a   Ro, Han ^a   Chang, Jae Hyun ^a   Lee, Hyun Hee ^a   Jung, Ji Yong ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

Calcitriol; Extracellular receptor for advanced glycation end products; Hemodialysis; Secondary hyperparathyroidism; Soluble receptor for advanced glycation end products

Indexed keywords

25 DIHYDROXYVITAMIN D3; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CALCITRIOL; CALCIUM; DIHYDROXYCOLECALCIFEROL; EXTRACELLULAR ADVANCED GLYCATION END PRODUCT RECEPTOR; INTERLEUKIN 6; MEMBRANE RECEPTOR; PARATHYROID HORMONE; PHOSPHORUS; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CLINICAL EFFECTIVENESS; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; VITAMIN BLOOD LEVEL;

CALCITRIOL; EXTRACELLULAR SPACE; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; RENAL DIALYSIS; SOLUBILITY;

EID: 84879391350     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.230.59     Document Type: Article

References (50)

1. Andress, D.L. (2008) Bone and mineral guidelines for patients with chronic kidney disease: a call for revision. Clin. J. Am. Soc. Nephrol., 3, 179-183.
2. Basta, G. (2008) Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis, 196, 9-21.
3. Basta, G., Leonardis, D., Mallamaci, F., Cutrupi, S., Pizzini, P., Gaetano, L., Tripepi, R., Tripepi, G., De Caterina, R. & Zoccali, C. (2010) Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int., 77, 225-231.
4. Basta, G., Sironi, A.M., Lazzerini, G., Del Turco, S., Buzzigoli, E., Casolaro, A., Natali, A., Ferrannini, E. & Gastaldelli, A. (2006) Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J. Clin. Endocrinol. Metab., 91, 4628-4634.
5. Bhan, I. & Thadhani, R. (2009) Vitamin D therapy for chronic kidney disease. Semin. Nephrol., 29, 85-93.
6. Block, G.A., Klassen, P.S., Lazarus, J.M., Ofsthun, N., Lowrie, E.G. & Chertow, G.M. (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol., 15, 2208-2218.
7. Block, G.A. & Port, F.K. (2000) Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am. J. Kidney Dis., 35, 1226-1237.
8. Bucala, R. & Cerami, A. (1992) Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv. Pharmacol., 23, 1-34.
9. Chang, J.H., Ro, H., Kim, S., Lee, H.H., Chung, W. & Jung, J.Y. (2012) Study on the relationship between serum 25-hydroxyvitamin D levels and vascular calcification in hemodialysis patients with consideration of seasonal variation in vitamin D levels. Atherosclerosis, 220, 563-568.
10. Cipollone, F., Iezzi, A., Fazia, M., Zucchelli, M., Pini, B., Cuccurullo, C., De Cesare, D., De Blasis, G., Muraro, R., Bei, R., Chiarelli, F., Schmidt, A.M., Cuccurullo, F. & Mezzetti, A. (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation, 108, 1070-1077.
11. Collins, A.J. (2003) Cardiovascular mortality in end-stage renal disease. Am. J. Med. Sci., 325, 163-167.
12. Falcone, C., Emanuele, E., D'Angelo, A., Buzzi, M.P., Belvito, C., Cuccia, M. & Geroldi, D. (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol., 25, 1032-1037.
13. Foley, R.N., Parfrey, P.S. & Sarnak, M.J. (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis., 32, S112-119.
14. Ganesh, S.K., Stack, A.G., Levin, N.W., Hulbert-Shearon, T. & Port, F.K. (2001) Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol., 12, 2131-2138.
15. Guerrero, F., Montes de Oca, A., Aguilera-Tejero, E., Zafra, R., Rodriguez, M. & Lopez, I. (2012) The effect of vitamin D derivatives on vascular calcification associated with inflammation. Nephrol. Dial. Transplant., 27, 2206-2212.
16. Hofmann, M.A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., Avila, C., Kambham, N., Bierhaus, A., Nawroth, P., Neurath, M.F., Slattery, T., Beach, D., McClary, J., Nagashima, M., Morser, J., Stern, D. & Schmidt, A.M. (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell, 97, 889-901.
17. Kalousova, M., Hodkova, M., Kazderova, M., Fialova, J., Tesar, V., Dusilova-Sulkova, S. & Zima, T. (2006) Soluble receptor for advanced glycation end products in patients with decreased renal function. Am. J. Kidney Dis., 47, 406-411.
18. Kendrick, J. & Chonchol, M.B. (2008) Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat. Clin. Pract. Nephrol., 4, 672-681.
19. Kim, J.K., Park, S., Lee, M.J., Song, Y.R., Han, S.H., Kim, S.G., Kang, S.W., Choi, K.H., Kim, H.J. & Yoo, T.H. (2012) Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis, 220, 208-214.
20. Koyama, H., Shoji, T., Yokoyama, H., Motoyama, K., Mori, K., Fukumoto, S., Emoto, M., Shoji, T., Tamei, H., Matsuki, H., Sakurai, S., Yamamoto, Y., Yonekura, H., Watanabe, T., Yamamoto, H. & Nishizawa, Y. (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 25, 2587-2593.
21. Koyama, H., Yamamoto, H. & Nishizawa, Y. (2007) RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol. Med., 13, 625-635.
22. Leonardis, D., Basta, G., Mallamaci, F., Cutrupi, S., Pizzini, P., Tripepi, R., Tripepi, G., De Caterina, R. & Zoccali, C. (2012) Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Nutr. Metab. Cardiovasc. Dis., 22, 748-755.
23. Lu, K.C., Tseng, C.F., Wu, C.C., Yeung, L.K., Chen, J.S., Chao, T.Y., Janckila, A.J., Yam, L.T. & Chu, P. (2006) Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism. Blood Purif., 24, 423-430.
24. Mahajan, N., Malik, N., Bahl, A. & Dhawan, V. (2009) Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with premature coronary artery disease. Atherosclerosis, 207, 597-602.
25. Mori, Y., Kosaki, A., Kishimoto, N., Kimura, T., Iida, K., Fukui, M., Nakajima, F., Nagahara, M., Urakami, M., Iwasaka, T. & Matsubara, H. (2009) Increased plasma S100A12 (ENRAGE) levels in hemodialysis patients with atherosclerosis. Am. J. Nephrol., 29, 18-24.
26. Nagpal, S., Na, S. & Rathnachalam, R. (2005) Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev., 26, 662-687.
27. Nakashima, A., Carrero, J.J., Qureshi, A.R., Miyamoto, T., Anderstam, B., Barany, P., Heimburger, O., Stenvinkel, P. & Lindholm, B. (2010) Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin. J. Am. Soc. Nephrol., 5, 2213-2219.
28. Park, C.W., Oh, Y.S., Shin, Y.S., Kim, C.M., Kim, Y.S., Kim, S.Y., Choi, E.J., Chang, Y.S. & Bang, B.K. (1999) Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis., 33, 73-81.
29. Park, L., Raman, K.G., Lee, K.J., Lu, Y., Ferran, L.J. Jr., Chow, W.S., Stern, D. & Schmidt, A.M. (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med., 4, 1025-1031.
30. Park, S., Yoon, S.J., Tae, H.J. & Shim, C.Y. (2011) RAGE and cardiovascular disease. Front. Biosci., 16, 486-497.
31. Patel, T.V. & Singh, A.K. (2009) Role of vitamin D in chronic kidney disease. Semin. Nephrol., 29, 113-121.
32. Ross, R. (1999) Atherosclerosis: an inflammatory disease. N. Engl. J. Med., 340, 115-126.
33. Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., Coresh, J., Culleton, B., Hamm, L.L., McCullough, P.A., Kasiske, B.L., Kelepouris, E., Klag, M.J., Parfrey, P., Pfeffer, M., Raij, L., Spinosa, D.J. & Wilson, P.W. (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation, 108, 2154-2169.
34. Schmidt, A.M., Yan, S.D., Yan, S.F. & Stern, D.M. (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest., 108, 949-955.
35. Shiotsu, Y., Mori, Y., Nishimura, M., Sakoda, C., Tokoro, T., Hatta, T., Maki, N., Iida, K., Iwamoto, N., Ono, T., Matsuoka, E., Kishimoto, N., Tamagaki, K., Matsubara, H. & Kosaki, A. (2011) Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin. J. Am. Soc. Nephrol., 6, 718-723.
36. Shoji, T., Shinohara, K., Kimoto, E., Emoto, M., Tahara, H., Koyama, H., Inaba, M., Fukumoto, S., Ishimura, E., Miki, T., Tabata, T. & Nishizawa, Y. (2004) Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol. Dial. Transplant., 19, 179-184.
37. Stenvinkel, P., Carrero, J.J., Axelsson, J., Lindholm, B., Heimburger, O. & Massy, Z. (2008) Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin. J. Am. Soc. Nephrol., 3, 505-521.
38. Talmor-Barkan, Y., Bernheim, J., Green, J., Benchetrit, S. & Rashid, G. (2011) Calcitriol counteracts endothelial cell proinflammatory processes in a chronic kidney disease-like environment. J. Steroid Biochem. Mol. Biol., 124, 19-24.
39. Talmor, Y., Bernheim, J., Klein, O., Green, J. & Rashid, G. (2008) Calcitriol blunts pro-atherosclerotic parameters through NFkappaB and p38 in vitro. Eur. J. Clin. Invest., 38, 548-554.
40. Teng, M., Wolf, M., Lowrie, E., Ofsthun, N., Lazarus, J.M. & Thadhani, R. (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med., 349, 446-456.
41. Teng, M., Wolf, M., Ofsthun, M.N., Lazarus, J.M., Hernan, M.A., Camargo, C.A. Jr. & Thadhani, R. (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol., 16, 1115-1125.
42. Tentori, F., Blayney, M.J., Albert, J.M., Gillespie, B.W., Kerr, P.G., Bommer, J., Young, E.W., Akizawa, T., Akiba, T., Pisoni, R.L., Robinson, B.M. & Port, F.K. (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis., 52, 519-530.
43. Valdivielso, J.M., Cannata-Andia, J., Coll, B. & Fernandez, E. (2009) A new role for vitamin D receptor activation in chronic kidney disease. Am. J. Physiol. Renal Physiol., 297, F1502-1509.
44. Wautier, J.L., Zoukourian, C., Chappey, O., Wautier, M.P., Guillausseau, P.J., Cao, R., Hori, O., Stern, D. & Schmidt, A.M. (1996) Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest., 97, 238-243.
45. Wu, C.C., Chang, J.H., Chen, C.C., Su, S.B., Yang, L.K., Ma, W.Y., Zheng, C.M., Diang, L.K. & Lu, K.C. (2011) Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism. Tohoku J. Exp. Med., 223, 153-159.
46. Yang, Z., Tao, T., Raftery, M.J., Youssef, P., Di Girolamo, N. & Geczy, C.L. (2001) Proinflammatory properties of the human S100 protein S100A12. J. Leukoc. Biol., 69, 986-994.
47. Yang, Z., Yan, W.X., Cai, H., Tedla, N., Armishaw, C., Di Girolamo, N., Wang, H.W., Hampartzoumian, T., Simpson, J.L., Gibson, P.G., Hunt, J., Hart, P., Hughes, J.M., Perry, M.A., Alewood, P.F. & Geczy, C.L. (2007) S100A12 provokes mast cell activation: a potential amplification pathway in asthma and innate immunity. J. Allergy Clin. Immunol., 119, 106-114.
48. Yonekura, H., Yamamoto, Y., Sakurai, S., Petrova, R.G., Abedin, M.J., Li, H., Yasui, K., Takeuchi, M., Makita, Z., Takasawa, S., Okamoto, H., Watanabe, T. & Yamamoto, H. (2003) Novel splice variants of the receptor for advanced glycation endproducts expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J., 370, 1097-1109.
49. Yonekura, H., Yamamoto, Y., Sakurai, S., Watanabe, T. & Yamamoto, H. (2005) Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J. Pharmacol. Sci., 97, 305-311.
50. Zakiyanov, O., Kalousova, M., Kriha, V., Zima, T. & Tesar, V. (2011) Serum S100A12 (EN-RAGE) levels in patients with decreased renal function and subclinical chronic inflammatory disease. Kidney Blood Press. Res., 34, 457-464.